Biological Basis of Novel Therapies for Myelodysplastic Syndrome

Title: Biological Basis of Novel Therapies for Myelodysplastic Syndrome

Volume: 2 Issue: 3

Author(s): Eyal C. Attar and Karen K. Ballen

Affiliation:

Keywords: Myelodysplastic syndrome, myeloid, apoptosis, cell cycle, 5q-, cancer stem cell

Abstract: Myelodysplastic syndrome (MDS) represents a group of malignant clonal disorders characterized by ineffective hematopoiesis and an accumulation of hematopoietic precursors in the bone marrow, frequently resulting in transformation to acute leukemia and death. However, recent understanding of MDS pathophysiology has provided novel treatment approaches with pharmacologic agents capable of manipulating pathways intrinsic and extrinsic to the malignant hematopoietic clone. These advances provide new therapeutic options for patients and provide a basis for further understanding and treatment of this disease.

Cite this article as:

Attar C. Eyal and Ballen K. Karen, Biological Basis of Novel Therapies for Myelodysplastic Syndrome, Current Cancer Therapy Reviews 2006; 2 (3) . https://dx.doi.org/10.2174/157339406777934708